Rankings
▼
Calendar
CTMX Q3 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$26M
+136.7% YoY
Gross Profit
$25M
94.6% margin
Operating Income
$11M
42.0% margin
Net Income
$3M
11.3% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
+6.7%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$18M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$221M
Total Liabilities
$272M
Stockholders' Equity
-$51M
Cash & Equivalents
$26M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$26M
$11M
+136.7%
Gross Profit
$25M
$10M
+158.3%
Operating Income
$11M
-$30M
+137.3%
Net Income
$3M
-$29M
+110.3%
← FY 2023
All Quarters
Q4 2023 →